Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 8/20 | 1.00 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104783 | 0.89 | HSD17B1 (0.80) | HSD17B1ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL13774778 | 0.84 | HSD17B1 (0.73) | HSD17B1ERCC1ERCC4LMNAALDH1A1 | |
| SCHEMBL4095452 | 0.83 | HSD17B1 (0.71) | HSD17B1KDM4EHPGDTSHRGAA | |
| SCHEMBL4096025 | 0.81 | HSD17B1 (0.69) | HSD17B1ALDH1A1HSD17B10ALOX15 | |
| SCHEMBL4091894 | 0.74 | HSD17B1 (1.00) | HSD17B1ERCC1ERCC4LMNAALDH1A1 | |
| SCHEMBL4101697 | 0.72 | HSD17B1 (0.57) | HSD17B1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL4091199 | 0.72 | HSD17B1 (0.80) | HSD17B1ERCC1ERCC4LMNAALDH1A1 | |
| SCHEMBL4102704 | 0.71 | HSD17B1 (0.55) | HSD17B1LMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL4101336 | 0.70 | HSD17B1 (0.64) | HSD17B1ERCC1ERCC4LMNAALDH1A1 | |
| SCHEMBL4095792 | 0.69 | HSD17B1 (0.67) | HSD17B1ERCC1ERCC4LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | HSD17B1 4/4885ERCC1 4154/4885ERCC4 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.